Yongxing Bao
Overview
Explore the profile of Yongxing Bao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
52
Citations
300
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Zhang Y, Lu P, Qi H, Mao R, Bao Y
Acta Parasitol
. 2024 Jan;
69(1):559-566.
PMID: 38233676
Purpose: Radiotherapy showed the potential to effectively kill the cysts of pulmonary cystic echinococcosis (CE). However, little is known about its safety. This study was designed to investigate the safety...
12.
Ma Z, Liang B, Wei R, Liu Y, Bao Y, Yuan M, et al.
Thorac Cancer
. 2023 Aug;
14(28):2839-2845.
PMID: 37596813
Background: Radiotherapy-induced esophagitis (RE) diminishes the quality of life and interrupts treatment in patients with non-small cell lung cancer (NSCLC) undergoing postoperative radiotherapy. Dosimetric models showed limited capability in predicting...
13.
Ma Z, Liu Y, Bao Y, Yuan M, Yang X, Men Y, et al.
Adv Radiat Oncol
. 2023 May;
8(4):101213.
PMID: 37152488
Purpose: Cardiopulmonary toxic effects may reduce the efficacy of postoperative radiation therapy (PORT) in patients with non-small cell lung cancer (NSCLC). However, few studies have examined whether the heart and...
14.
Yang X, Zhao L, Shi A, Chen C, Cao J, Zhang Y, et al.
Am J Gastroenterol
. 2023 Mar;
118(8):1344-1352.
PMID: 36972240
Introduction: Adjuvant radiotherapy is recommended for pT1b esophageal squamous cell cancer (ESCC) after endoscopic submucosal dissection (ESD). However, it is unclear whether additional radiotherapy can improve patient survival. This study...
15.
Liu Y, Bao Y, Yang X, Sun S, Yuan M, Ma Z, et al.
Front Immunol
. 2023 Feb;
14:1117448.
PMID: 36761760
Background: Significant progress has been made in the investigation of neoadjuvant immune-chemoradiotherapy (NICRT) and neoadjuvant immune-chemotherapy (NICT) on the outcomes of esophageal cancer patients. To summarize the current developments, a...
16.
Bao Y, Hui Z
Zhongguo Fei Ai Za Zhi
. 2023 Jan;
25(12):870-876.
PMID: 36617473
Patients with N2 non-small cell lung cancer (NSCLC) were heterogeneous groups and required further stratification. The International Society for the Study of Lung Cancer (IASLC) divided N2 into three sub-stages:...
17.
18.
Yuan M, Zhai Y, Men Y, Zhao M, Sun X, Ma Z, et al.
Thorac Cancer
. 2022 Oct;
13(23):3331-3340.
PMID: 36281217
Background: Combining antiangiogenic therapy with radioimmunotherapy is believed to further improve antitumor efficacy, but there is still a lack of evidence to support this. This study aimed to investigate the...
19.
20.
Bao Y, Ma Z, Yuan M, Wang Y, Men Y, Hui Z
Thorac Cancer
. 2022 Jul;
13(17):2515-2523.
PMID: 35891585
Purpose: The best pattern of neoadjuvant therapy for resectable locoregional esophageal cancer has not been determined. Our study evaluated the efficacy and postoperative events of different treatments using the Bayesian...